Clinical Trial Update: Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris) [Phase 3]

View source ↗

Summary

Phase 3 long-term follow-up study of cantharidin (YCANTH VP-102/TO-208) for common warts (verruca vulgaris) is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Warts
• Verruca Vulgaris

Drugs mentioned

• YCANTH (VP-102/TO-208) (cantharidin)

Snippet

Sponsor: Verrica Pharmaceuticals Inc. | Conditions: Common Warts (Verruca Vulgaris), Common Warts | Phase 3 | Status: NOT_YET_RECRUITING